Clinical Outcomes Following Personalized Gut Microbiota-Targeted Therapy in Children with Atopic Dermatitis and Laboratory-Confirmed Dysbiosis: A Single-Arm Prospective Pilot Study
Nutrients · 06.08.2026 · 18 (15) · 2572
DOI: 10.3390/nu18152572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 06.08.2026. Verfasst von Raluca-Gabriela Miulescu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dysbiosis, Gastrointestinal Microbiome, Probiotics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background/Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin disease in which gut–skin axis dysregulation is increasingly implicated. We conducted a prospective pilot study to describe the clinical evolution of pediatric AD following individualized, stool-guided microbiota-targeted therapy and to explore whether baseline dysbiosis markers predict outcomes beyond baseline disease severity.
Methods
Twenty-one children with AD and laboratory-confirmed gut dysbiosis were enrolled consecutively at a tertiary pediatric center in Romania in a single-arm prospective pilot study. Gut microbiota was assessed using targeted culture-based stool analysis, generating a Flora Index and a binary High Putrefaction Flora classification. Individualized treatment consisted of strain-specific probiotics, prebiotics, and antifungals when indicated. Disease severity was assessed using the Patient-Oriented Eczema Measure (POEM) and Scoring Atopic Dermatitis (SCORAD) at baseline, 30 days, and 90 days. Longitudinal changes were evaluated using repeated-measures ANOVA and hierarchical regression models.
Results
High Putrefaction Flora was present in 71.4% of participants. Mean POEM decreased from 14.67 ± 5.22 at baseline to 7.10 ± 3.82 at 90 days, while mean SCORAD decreased from 41.66 ± 15.28 to 17.93 ± 11.68 (both p < 0.001). Approximately 76% of participants achieved a ≥50% reduction in POEM, and 71% achieved a ≥50% reduction in SCORAD. Individualized microbiota-targeted therapy was associated with substantial improvements in both clinical and patient-reported disease severity over the 90-day follow-up. Although children with High Putrefaction Flora exhibited higher disease severity scores in unadjusted analyses, baseline disease severity was the only significant predictor of 90-day outcomes. The Flora Index provided no independent explanatory value.
Conclusions
In this exploratory single-arm pilot study, individualized microbiota-targeted therapy was associated with substantial and clinically meaningful improvement in AD severity over 90 days. Dysbiosis markers were associated with disease burden but did not independently predict outcomes, suggesting that they may function primarily as indicators of baseline severity rather than prognostic biomarkers. Because of the uncontrolled study design, causal inferences regarding treatment effects cannot be made, and these findings should be considered hypothesis-generating. Adequately powered randomized controlled trials are required to determine the efficacy of individualized microbiota-targeted interventions in pediatric atopic dermatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
- Dermatology Department, Saint Constantin Hospital, 500388 Brasov, Romania.
- Clinical Hospital of Obstetrics and Gynecology "Prof. Dr. P.Sirbu", 060251 Bucharest, Romania.
- Department III Functional Science, Discipline of Medical Informatics and Biostatistics, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Pax Clinic, 020951 Bucharest, Romania.
- Pediatrics Department, National Institute for Mother and Child Health "Alessandrescu-Rusescu", 20382 Bucharest, Romania.
ORCID-Profile: Ioana Roşca, Ruxandra-Cristina Marin, Călin Muntean, Alexandru-Neculai Pavel, Smaranda Stoleru, Elena Poenaru, Daniela Eugenia Popescu, Oana Andreia Coman
Zitieren
APA
Miulescu, R. G., Roşca, I., Marin, R. C., Muntean, C., Pavel, A. N., Stoleru, S., Constantin, A. T., Poenaru, E., Parliteanu, O. A., Popescu, D. E., & Coman, O. A. (2026). Clinical Outcomes Following Personalized Gut Microbiota-Targeted Therapy in Children with Atopic Dermatitis and Laboratory-Confirmed Dysbiosis: A Single-Arm Prospective Pilot Study. Nutrients, 18(15), 2572. https://doi.org/10.3390/nu18152572
Vancouver
Miulescu RG, Roşca I, Marin RC, Muntean C, Pavel AN, Stoleru S, et al. Clinical Outcomes Following Personalized Gut Microbiota-Targeted Therapy in Children with Atopic Dermatitis and Laboratory-Confirmed Dysbiosis: A Single-Arm Prospective Pilot Study. Nutrients. 2026;18(15):2572. doi:10.3390/nu18152572
BibTeX
@article{Miulescu2026,
author = {Miulescu, Raluca-Gabriela and Roşca, Ioana and Marin, Ruxandra-Cristina and Muntean, Călin and Pavel, Alexandru-Neculai and Stoleru, Smaranda and Constantin, Andreea Teodora and Poenaru, Elena and Parliteanu, Oana Andreea and Popescu, Daniela Eugenia and Coman, Oana Andreia},
title = {Clinical Outcomes Following Personalized Gut Microbiota-Targeted Therapy in Children with Atopic Dermatitis and Laboratory-Confirmed Dysbiosis: A Single-Arm Prospective Pilot Study},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {15},
pages = {2572},
doi = {10.3390/nu18152572}
}
EUVIMED